Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H1 2015

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia-Pipeline Review, H1 2015', provides an overview of the B-Cell Chronic Lymphocytic Leukemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for B-Cell Chronic Lymphocytic Leukemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

B-Cell Chronic Lymphocytic Leukemia Overview 9

Therapeutics Development 10

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia-Overview 10

Pipeline Products for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis 11

B-Cell Chronic Lymphocytic Leukemia-Therapeutics under Development by Companies 12

B-Cell Chronic Lymphocytic Leukemia-Therapeutics under Investigation by Universities/Institutes 14

B-Cell Chronic Lymphocytic Leukemia-Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

B-Cell Chronic Lymphocytic Leukemia-Products under Development by Companies 18

B-Cell Chronic Lymphocytic Leukemia-Products under Investigation by Universities/Institutes 20

B-Cell Chronic Lymphocytic Leukemia-Companies Involved in Therapeutics Development 21

AbbVie Inc. 21

Amgen Inc. 22

BioNovion B.V. 23

Celgene Corporation 24

Dynavax Technologies Corporation 25

Eisai Co., Ltd. 26

F. Hoffmann-La Roche Ltd. 27

iDD biotech SAS 28

Immunomedics, Inc. 29

Juno Therapeutics Inc. 30

MABLife S.A.S 31

Nippon Shinyaku Co., Ltd. 32

Noxxon Pharma AG 33

Ono Pharmaceutical Co., Ltd. 34

Regeneron Pharmaceuticals, Inc. 35

SBI Biotech Co., Ltd. 36

TheraMAB LLC. 37

Vivia Biotech, S.L. 38

B-Cell Chronic Lymphocytic Leukemia-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Target 40

Assessment by Mechanism of Action 42

Assessment by Route of Administration 44

Assessment by Molecule Type 46

Drug Profiles 48

202-b-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

alemtuzumab biosimilar-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

AMG-319-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

bafetinib-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

BION-1301-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

Cell Therapy for B-Cell Chronic Lymphocytic Leukemia-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

Cell Therapy for Hematological Malignancies-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Cell Therapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

Cell Therapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

Cell Therapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Cell Therapy to Target CD16 for CLL and NHL-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Cell Therapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Cell Therapy to Target CD19 for Cancer-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

Cell Therapy to Target CD19 for Oncology-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

E-7449-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

GNKS-356-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

IDD-001-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

IDD-002-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

ilorasertib-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

lenalidomide-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

MAT-304-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

olaptesed pegol-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

ONO-4059-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

REGN-1979-Drug Profile 82

Product Description 82

Mechanism of Action 82

R&D Progress 82

SD-101-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Small Molecules for Oncology-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

TAB-08-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

tocilizumab-Drug Profile 88

Product Description 88

Mechanism of Action 88

R&D Progress 88

Vivia-009-Drug Profile 91

Product Description 91

Mechanism of Action 91

R&D Progress 91

B-Cell Chronic Lymphocytic Leukemia-Recent Pipeline Updates 92

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects 107

B-Cell Chronic Lymphocytic Leukemia-Discontinued Products 108

B-Cell Chronic Lymphocytic Leukemia-Product Development Milestones 109

Featured News & Press Releases 109

Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 109

Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 110

Appendix 111

Methodology 111

Coverage 111

Secondary Research 111

Primary Research 111

Expert Panel Validation 111

Contact Us 111

Disclaimer 112

List of Tables

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2015 10

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 13

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Late Stage Development, H1 2015 15

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Development, H1 2015 17

Products under Development by Companies, H1 2015 18

Products under Development by Companies, H1 2015 (Contd..1) 19

Products under Investigation by Universities/Institutes, H1 2015 20

B-Cell Chronic Lymphocytic Leukemia-Pipeline by AbbVie Inc., H1 2015 21

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Amgen Inc., H1 2015 22

B-Cell Chronic Lymphocytic Leukemia-Pipeline by BioNovion B.V., H1 2015 23

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Celgene Corporation, H1 2015 24

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Dynavax Technologies Corporation, H1 2015 25

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Eisai Co., Ltd., H1 2015 26

B-Cell Chronic Lymphocytic Leukemia-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 27

B-Cell Chronic Lymphocytic Leukemia-Pipeline by iDD biotech SAS, H1 2015 28

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Immunomedics, Inc., H1 2015 29

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Juno Therapeutics Inc., H1 2015 30

B-Cell Chronic Lymphocytic Leukemia-Pipeline by MABLife S.A.S, H1 2015 31

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Nippon Shinyaku Co., Ltd., H1 2015 32

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Noxxon Pharma AG, H1 2015 33

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 34

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 35

B-Cell Chronic Lymphocytic Leukemia-Pipeline by SBI Biotech Co., Ltd., H1 2015 36

B-Cell Chronic Lymphocytic Leukemia-Pipeline by TheraMAB LLC., H1 2015 37

B-Cell Chronic Lymphocytic Leukemia-Pipeline by Vivia Biotech, S.L., H1 2015 38

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Stage and Target, H1 2015 41

Number of Products by Stage and Mechanism of Action, H1 2015 43

Number of Products by Stage and Route of Administration, H1 2015 45

Number of Products by Stage and Molecule Type, H1 2015 47

B-Cell Chronic Lymphocytic Leukemia Therapeutics-Recent Pipeline Updates, H1 2015 92

B-Cell Chronic Lymphocytic Leukemia-Dormant Projects, H1 2015 107

B-Cell Chronic Lymphocytic Leukemia-Discontinued Products, H1 2015 108

List of Figures

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2015 10

Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 16

Comparative Analysis by Early Stage Products, H1 2015 17

Assessment by Monotherapy Products, H1 2015 39

Number of Products by Top 10 Targets, H1 2015 40

Number of Products by Stage and Top 10 Targets, H1 2015 40

Number of Products by Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 42

Number of Products by Top 10 Routes of Administration, H1 2015 44

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 44

Number of Products by Top 10 Molecule Types, H1 2015 46

Number of Products by Stage and Top 10 Molecule Types, H1 2015 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Amgen Inc.

BioNovion B.V.

Celgene Corporation

Dynavax Technologies Corporation

Eisai Co., Ltd.

F. Hoffmann-La Roche Ltd.

iDD biotech SAS

Immunomedics, Inc.

Juno Therapeutics Inc.

MABLife S.A.S

Nippon Shinyaku Co., Ltd.

Noxxon Pharma AG

Ono Pharmaceutical Co., Ltd.

Regeneron Pharmaceuticals, Inc.

SBI Biotech Co., Ltd.

TheraMAB LLC.

Vivia Biotech, S.L.

B-Cell Chronic Lymphocytic Leukemia Therapeutic Products under Development, Key Players in B-Cell Chronic Lymphocytic Leukemia Therapeutics, B-Cell Chronic Lymphocytic Leukemia Pipeline Overview, B-Cell Chronic Lymphocytic Leukemia Pipeline, B-Cell Chronic Lymphocytic Leukemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com